Notice NOT-MH-21-015 from the NIH Guide for Grants and Contracts

Notice NOT-MD-21-006 from the NIH Guide for Grants and Contracts

Notice NOT-MD-21-005 from the NIH Guide for Grants and Contracts

Notice NOT-HD-20-034 from the NIH Guide for Grants and Contracts

£50,000 - £65,000 depending on experience, plus benefits and share options: Singular Talent: How would you like to spend your time exploring genomic dark matter to find novel drug targets? Read on to learn more..... Oxford, Oxfordshire (GB)

Notice NOT-HL-20-818 from the NIH Guide for Grants and Contracts

Notice NOT-NS-21-010 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-314 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.

Funding Opportunity PAR-20-313 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical, and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI. This FOA will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants should have assays that work on human samples and whose importance is well justified for development into clinical assays. As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance thedurability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH2 phase of this FOA supports analytical validation of assays for these molecular/cellular/imaging markers, which must be achieved within 2 years before assays may undergo clinical validation. The UH3 phase of this FOA supports clinical validation of analytically validated assays for up to 3 years using well-annotated biospecimens from retrospective or prospective clinical trials or studies. This FOA may be used to validate existing assays for use in other cancer clinical trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this FOA will require multi-disciplinary collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientist.

Funding Opportunity PA-20-272 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm.

Competitive Salary: EMBL: Metadata bioinformatician - European Genome-phenome Archive Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Bioinformatician - parasite genomics Location: Cambridge, Cambridgeshire, England

Notice NOT-TR-21-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-ES-20-018 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to fully integrate recent innovative advances of in vitro functional genomics tools/technologies and approaches for environmental health and toxicology applications. The overall goal of this NIEHS led initiative is to generate proof-of-principle studies incorporating these new in vitro approaches, together with well characterized exposures, to further our understanding of gene-environment (G x E) interactions in complex human disorders.

Notice NOT-EY-21-002 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-094 from the NIH Guide for Grants and Contracts

The University of Wisconsin-Madison fulfills its public mission by creating a welcoming and inclusive community for people from every background - people who as…
From University of Wisconsin–Madison - Fri, 09 Oct 2020 18:58:01 GMT - View all Madison, WI jobs

Notice NOT-EB-20-013 from the NIH Guide for Grants and Contracts

Notice NOT-CA-21-004 from the NIH Guide for Grants and Contracts

Master’s or PhD in Bioinformatics or related Life or Computational Science or Bachelor degree with 3+ years experience.
From IntelliGen Technologies - Fri, 09 Oct 2020 12:23:11 GMT - View all Windsor, WI jobs